Molbio Diagnostics LimitedPharmaceuticals & HealthcareMOLBIO
Q1 FY27 concall · earnings callMolbio Diagnostics Limited
Q1 FY27 was led by the Truenat point-of-care molecular platform with recurring kit sales driving revenue, while management pointed to TB scale-up, HPV rollout, and U.S. and Europe expansion as next growth drivers.
Numbers
| Metric | This quarter | Change | Five-quarter trend |
|---|---|---|---|
| Revenue from operations (Q1 FY27) | ₹408 Cr | — | |
| EBITDA (Q1 FY27) | ₹104 Cr | — | |
| Profit after tax (Q1 FY27) | ₹52.7 Cr | — | |
| Test kits sold (Q1 FY27) | 62.4 lakh kits | — | |
| Devices sold (Q1 FY27) | 164 devices | — | |
| Export revenue (Q1 FY27) | ₹67 Cr | — |
TL;DR
- Revenue from operations was ₹408 crores with EBITDA of ₹104 crores and profit after tax of ₹52.7 crores
- Sold 164 devices and 62.4 lakh kits in Q1 FY27, with about 75% of revenues from test kits
- Export revenue was around ₹67 crores or 16% of total revenue, including catch-up of deferrals from Q4 FY26
- Installed base is close to 12,500 machines across 90-plus countries with 43 assays for 30 different diseases
Said on the call
“It's not a quarter-on-quarter business because of the fact that we operate in public health, so no quarter is going to be linear, whether sequentially or year on year.”
From the Q&A
| Topic | What management said |
|---|---|
| HPV | Truenat HPV test completed AIIMS-led validation as the only test from India to meet all the international criteria, found cost-effective for screening women in the age group of 30 to 45, with WHO prequalification in process and rollout into national program awaited |
| OptraScan | OptraScan received U.S. FDA clearance in July for machine plus workflow including software and AI; focus is U.S. market with discussions with large laboratory and hospital networks, but no profit expected in FY ‘27 |
| Device lifecycle and closed system | Truenat is a closed system where reagents work only on company devices; early installations from nearly 6-7 years are still running with no replacement cycle yet, and same device can test different diseases with disease-specific consumables |
| TB visibility | TB remains largely public TB; reached only about 8,000 to 9,000 of about 25,000 to 30,000 TB diagnostic centers, with remaining centers on microscopy, and current government rate contract is valid for two years |
| Capacity and mix | Capacity utilization is about 58% on test kits and about 42% for devices, with standard gross margin of 60% to 63% and about 75% of revenues from test kits; realization moves with device variant mix and geography |
Guidance
- Grow top line at roughly about 25% for the year with EBITDA of about 24% to 25%, to be tracked on an annual basis
- Continue R&D spend at 5% to 6% of revenue, with bulk for newer platforms and limited capex beyond IPO-funded automation and Bangalore R&D center
- OptraScan not expected to turn profitable in FY ‘27, with meaningful contribution expected from '28 and '29 onwards
Source
Summary written from the transcript filed by Molbio Diagnostics Limited for the call held on 8 Sept 2026; published 12 Sept 2026, 10:33 IST.
More Q1 FY27 concalls ·How verification works ·Report an error